| Title |
Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
|
|---|---|
| Published in |
OncoTargets and therapy, November 2012
|
| DOI | 10.2147/ott.s36330 |
| Pubmed ID | |
| Authors |
Isabel Fernandes, Teresa R Pacheco, Adília Costa, Ana C Santos, Ana R Fernandes, Mara Santos, António G Oliveira, Sandra Casimiro, António Quintela, Afonso Fernandes, Madalena Ramos, Luís Costa |
| Abstract |
Somatostatin analogs (SSAs) are used as part of standard treatment for advanced neuroendocrine tumors (NETs). The mechanisms behind the antiproliferative action of SSAs remain largely unknown, but a connection with the mammalian target of rapamycin (mTOR) signaling pathway has been suggested. Our purpose was to evaluate the activation status of the AKT/mTOR pathway in advanced metastatic NETs and identify biomarkers of response to SSA therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 5% |
| Portugal | 1 | 5% |
| France | 1 | 5% |
| Unknown | 16 | 84% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 26% |
| Professor > Associate Professor | 3 | 16% |
| Librarian | 2 | 11% |
| Student > Master | 2 | 11% |
| Student > Bachelor | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 4 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 47% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Veterinary Science and Veterinary Medicine | 1 | 5% |
| Psychology | 1 | 5% |
| Agricultural and Biological Sciences | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 6 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2012.
All research outputs
#23,228,954
of 25,887,951 outputs
Outputs from OncoTargets and therapy
#2,099
of 3,017 outputs
Outputs of similar age
#183,116
of 203,757 outputs
Outputs of similar age from OncoTargets and therapy
#12
of 16 outputs
Altmetric has tracked 25,887,951 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,017 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 203,757 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.